US companies have begun recruiting for a CRISPR-based gene-editing trial to treat β-thalassemia, Stat News reports.
The Telegraph reports that UK regulators gave CRISPR Therapeutics the go-ahead for its beta thalassemia clinical trial.
Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.
The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.
CRISPR Therapeutics is moving toward clinical trials for beta thalassemia and sickle cell disease treatments, according to Wired.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
The firm will use MaxCyte's cell transfection platform to edit hematopoietic stem cells with CRISPR/Cas9 in hemoglobinopathy and SCID.
UC can still salvage its CRISPR IP rights after last week's decision, but a long-shot appeal in federal court is the only possibility for total victory.
The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.